Impact of target-specific oral anticoagulants on transitions of care and outpatient care models

Journal of Thrombosis and Thrombolysis

Volumn 35, Issue 3, 2013, Pages 304-311

  Wittkowsky, Ann K ^a,b  

^a UNIVERSITY OF WASHINGTON MEDICAL CENTER   (United States)

^b UNIVERSITY OF WASHINGTON   (United States)

Author keywords

Anticoagulation; Anticoagulation clinic; Apixaban; Dabigatran; Rivaroxaban; Transition of care

Indexed keywords

ANTICOAGULANT AGENT; APIXABAN; DABIGATRAN; HEPARIN; LOW MOLECULAR WEIGHT HEPARIN; RIVAROXABAN; WARFARIN;

ANTICOAGULANT THERAPY; BLEEDING; CONFERENCE PAPER; DIET; HEALTH CARE ACCESS; HEALTH CARE UTILIZATION; HOSPITAL DISCHARGE; HOSPITAL PATIENT; HOSPITAL READMISSION; HUMAN; INTERNATIONAL NORMALIZED RATIO; LABORATORY TEST; LIFESTYLE; MEDICARE; MEDICATION ERROR; OUTPATIENT CARE; PATIENT CARE; PATIENT COMPLIANCE; PATIENT EDUCATION; PATIENT MONITORING; PATIENT SAFETY; PRIORITY JOURNAL; REIMBURSEMENT; RISK BENEFIT ANALYSIS; SELF CARE; SELF MEDICATION; TRANSITION OF CARE; TREATMENT OUTCOME; UNSPECIFIED SIDE EFFECT;

ADMINISTRATION, ORAL; AMBULATORY CARE; ANTICOAGULANTS; FEMALE; HUMANS; MALE; MONITORING, PHYSIOLOGIC; UNITED STATES;

EID: 84876666098     PISSN: 09295305     EISSN: 1573742X     Source Type: Journal    
DOI: 10.1007/s11239-013-0879-y     Document Type: Conference Paper

References (43)

1. Adam SS, McDuffie JR et al (2012) Comparative effectiveness of warfarin and new oral anticoagulants for the management of atrial fibrillation and venous thromboembolism: a systematic review. Ann Intern Med. doi: 10.7326/0003-4819- 157-10-201211200-00532
2. National Transitions of Care Coalition. Improving transitions of care: the vision of the National Transition of Care Coalition. http:/ www.ntocc.org/portals/0/policypaper.pdf. Accessed 28 Dec, 2012
3. Centers for Disease Control and Prevention. National Hospital Discharge Survey 2010. http://www.cdc.gov/nchs/nhds.htm. Accessed 28 Dec, 2012
4. Agency for Healthcare Research and Quality. Healthcare Cost and Utilization Project 2009. http://www.hcup-us.ahrq.gov/reports/factsandfigures/ 2009/TOC-2009.jsp. Accessed 28 Dec, 2012
5. Moore C, Wisnivesky J, Williams S, McGinn T (2003) Medical errors related to discontinuity of care from and inpatient to an outpatient setting. J Gen Intern Med 18:646-651 (Pubitemid 37047038)
6. Forster AJ, Murff HJ, Peterson JF, Chandi TK, Bates DW (2003) The incidence and severity of adverse events affecting patients after discharge from the hospital. Ann Intern Med 138:161-167 (Pubitemid 36231621)
7. Boockvar K, Fishman E, Kyriacou CK, Monias A, Gavi S, Cortes T (2004) Adverse events due to discontinuations in durg use and dose changes in patients transferred between acute and long term care facilities. Arch Intern Med 164:545-550 (Pubitemid 38314451)
8. Gray SL, Mahoney JE, Blough DK (1999) Adverse drug events in elderly patients receiving home health services following hospital discharge. Ann Pharmaoctherapy 33:1147-1153
9. Rozich J, Resar R (2001) Medication safety: one organization's aproach to the challenge. J Clin Outcomes Manag 8:27-34
10. Jencks SF, Williams MV, Coleman EA (2009) Rehospitalizations among patients in the Medicare Fee-for-Service program. New Engl J Med 360:1418-1428
11. Center for Medicare and Medicaid Services. Readmissions reduction program. http://www.cms.gov/Medicare/Medicare-Fee-for-Service-Payment/ AcuteInpatientPPS/Readmissions-Reduction-Program.html. Accessed December 28, 2012
12. Jack BW, Chetty VK, Anthony D, Greenwald JL, Sanchez GM et al (2009) A reengineered hospital discharge program to decrease rehospitalization. Ann Intern Med 150:178-187
13. Coleman EA, Parry C, Chalmers S, Min Sung-joon (2006) The care transitions intervention. Results of a randomized controlled trial. Arch Intern Med 166:1822-1828 (Pubitemid 44455163)
14. Naylor MD, Brooten D, Campbell R, Jocbsen BS, Mezey MD et al (1999) Comprehensive discharge planning and home followup of hospitalized elders. A randomized controlled trial. JAMA 281:613-620 (Pubitemid 29098061)
15. Boult C, Reider L, Leff B, Frick KD, Boyd CM, Wolff JL et al (2011) The effect of guided care teams on the use of health services. Results from a cluster-randomized controlled trial. Arch Intern Med 171:460-466
16. Bradley EH, Curry L, Horwitz LI, Sipsma H, Thompson JW et al (2012) Contemporary evidence about hospital strategies for reducing 30-day readmissions. A national study. J Am Coll Cardiol 60:607-614
17. Hansen LO, Young RS, Hinami K, Leung A, Williams MV (2011) Interventions to reduce 30-day rehospitalization: a systematic review. Ann Intern Med 155:520-528
18. Snow V, Beck D, Budnitz T, Miller DC, Potter J et al (2009) Transitions of care consensus policy statement. J Hosp Med 4:364-370
19. The Joint Commission. National Patient Safety Goals 2013. http://www.jointcommission.org/assets/1/18/NPSG-Chapter-Jan2013-HAP.pdf. Accessed 28 Dec, 2012
20. APhA, ASHP, Steeb D, Webster L (2012) Improving care transitions: optimizing medication reconciliation. J Am Pharm Assoc 52:e43-e52
21. Classen DC, Jaser L, Budnitz DS (2010) Adverse drug events among hospitalized Medicare patients: epidemiology and national estimates from a new approach to surveillance. Jt Comm J Qual Patient Saf 36:12-21
22. Piazza G, Nguyen TN, Cios D, Labreche M, Hohlfelder B et al (2011) Anticoagulation-associated adverse drugeents. Am J Med 124:1136-1142
23. Hafner JW, Belknap SM, Squillante MD, Bucheit KA (2002) Adverse drug events in emergency department patients. Ann Emerg Med 39:258-267 (Pubitemid 34219639)
24. Budnitz DS, Pollock DA, Mendelsohn AB, Weidenback KN, McDonald AK, Annest JL (2005) Emergency department visits for outpatient adverse drug events: demonstration for a national surveillance system. Ann Emerg Med 45:197-206
25. Budnitz DS, Lovegrove MC, Shehab N, Richards CL (2011) Emergency hospitalizations for adverse drug events in older Americans. N Engl J Med 365:2002-2012
26. Shehab N, Sperling LS, Kegler SR, Budnitz DS (2010) National estimates of emergency department visits for hemorrhage related adverse events from clopidogrel plus aspirin and from warfarin. Arch Intern Med 170:1926-1933
27. Institute of Safe Medication Practices. high alert medications list. http://www.ismp.org/Tools/highAlertMedicationLists.asp. Accessed 28 Dec, 2012
28. Nutescu EA, Wittkowsky AK, Burnett A, Merli G (2013) Consensus guidelines for inpatient management of anticoagulant therapy: from the anticoagulation forum. Ann Pharmacotherapy (in press)
29. Kucukarslan SN, Peters M, Mlynarek M, Nafziger DA (2003) Pharmacists on rounding teams reduce preventable adverse drug events in hospital general medicine units. Arch Intern Med 163:2014-2018 (Pubitemid 37151242)
30. Dager WE, Gulseth MP (2007) Implementing anticoagulation management by pharmacists in the inpatient setting. Am J Health Syst Pharm 64:1071-1079 (Pubitemid 46801539)
31. Burnett A, D'Angio R, Earl LE, Garcia D (2011) Challenges and benefits of an inpatient anticoagulation service: one hospital's experience. J Thromb Thrombolysis 31:344-352
32. Jennings HR, Miller EC, Williams TS, Tichenor SS, Woods EA (2008) Reducing anticoagulation medication adverse events and avoidable patient harm. Jt Comm J Qual Patient Saf 34:196-200
33. Bond CA, Raehl CL (2004) Pharmacist-provided anticoagulation management in United States hospitals: death rates, length of stay, Medicare charges, bleeding complications, and transfusions. Pharmacotherapy. 24:953-963 (Pubitemid 39025194)
34. Holbrook A, Schulman S, Witt DM, Vandvick PO, Fish J et al (2012) Evidence-based management of anticoagulant therapy antithrombotic therapy and prevention of thrombosis 9th ed: American College of Chest Physicians evidence-based clinical practice guidelines. Chest 141(suppl):e152s-e184s
35. Schillig J, Kaatz S, Hudson M, Krol GD, Szandik EG, Kalus J (2011) Clinical and safety impact of an inpatient pharmacist-directed anticoagulation service. J Hosp Med 6:322-328
36. Pernod G, Labarere J, Yver J et al (2008) EDU'AVK: reduction of oral anticoagulant related adverse events after patient education: a prosepective multicenter open randomized study. J Gen Intern Med 23:1441-1446
37. Tang EO, Lai CS, Lee KK et al (2003) Relationship between patients' warfarin knowledge and anticoagulant control. Ann Pharmacother 37:34-39 (Pubitemid 36068595)
38. Wilhelm SM, Petrovitch EA (2011) Implementation of an inpatient anticoagulation teaching service: expanding the role of pharmacy students and residents in patient education. Am J Health Syst Pharm 68:2086-2093
39. Nutescu EA, Spinler SA, Dager WE, Bussey HI (2004) Transitioning from traditional to novel anticoagulants: the impact of oral direct thrombin inhibitors on anticoagulation management. Pharmacotherapy 24(10 pt 2):199-202s (Pubitemid 39304991)
40. Gulseth MP, Wittkowsky AK, Fanikos J, Spinler SA, Dager WE, Nutescu EA (2011) Dabigatran etexilate in clinical practice. Confronting challenges to improve safety and effectiveness. Pharmacotherapy 31:1232-1249
41. US Food and Drug Administration. Medication Guides. http://www.fda.gov/ Drugs/DrugSafety/ucm085729.htm. Accessed 28 Dec, 2012
42. Spinler SA, Willey VJ (2011) A patient's guide to taking dabigatran etexilate. Circulation 124:e209-e211
43. Cios D, Fanikos J (2012) Rivaroxaban to prevent pulmonary embolism after hip or knee replacement. Circulation 125:e542-e544